Navigation Links
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
Date:3/5/2008

4,195 5,566 8,964

Impairment of long-lived

asset held for sale 735 - 735 -

-------------------------------------------------------------------------

21,904 18,394 76,822 62,570

-------------------------------------------------------------------------

Loss from operations (11,664) (6,457) (34,754) (23,771)

-------------------------------------------------------------------------

Other revenues (expenses)

Interest income 535 703 1,904 1,441

Interest expense (23) 14 (85) (1,433)

Foreign exchange gain

(loss) (269) 384 (1,035) 319

Loss on disposal of

equipment (28) - (28) -

Gain on disposal of

long-term investment - 409 - 409

Other - (163) - -

-------------------------------------------------------------------------

215 1,347 756 736

-------------------------------------------------------------------------

Share in the results

of an affiliated

company - 1,575 - 1,575

-------------------------------------------------------------------------

Loss before Income taxes (11,449) (3,535) (33,998) (21,460)

Income tax recovery

(expense) (2,405) 26,061 1,961 29,037

-------------------------------------------------------------------------

Net earnings (loss) from

continuing operations (13,854) 22,526 (32,037) 7,577

Net earnings (loss) from

discont
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
2. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
3. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
4. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
7. AEterna Zentaris Announces Outcome of Managements Strategic Review
8. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
9. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
10. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
11. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... receipt of notice on July 18, 2014 from ... has accepted the CorMedix plan to regain compliance ... a result, the NYSE-MKT is continuing the Company,s ...
(Date:7/24/2014)... balances – 4 steps – One Recommendation: the web-based ... narrows down the mass of product choices to a ... , First, select the working environment, then enter the ... define the accuracy – it’s really that simple. Specifying ... to models that fit best with the customer’s industry ...
(Date:7/24/2014)... 2014 As part of the long-term ... the MENA region during 2014 with potential global expansion. ... agreement with DZS to manage our clinical trials globally ... VP of R&D and President of SBI pharmaceuticals MENA, ... practices with a focus on utilizing eClinical software and ...
(Date:7/23/2014)... Heroic worldwide conservation efforts have made great strides in ... in China, there are over 65 giant panda reserves ... But despite these efforts, just 1596 pandas remain in ... and zoos hope to save the panda by improving ... to the wild. Just how are these high-profile programs ...
Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... , THE WOODLANDS, Texas, Sept. 9 ... company focused on discovering and developing breakthrough treatments for human disease, announced ... president and chief executive officer, will present at the Morgan Stanley Global ... York on Tuesday, September 15, 2009 at 1:35 p.m. Eastern Time. ...
... ... software makes its debut at leading industry conferences. , ... Cambridge, MA (PRWEB) September 9, 2009 -- Akaza Research, the leading ... flagship product, OpenClinica, at two major industry conferences this fall. , , ,Representatives from Akaza ...
... Ontario, Sept. 8 Helix BioPharma Corp. (TSX, FSE: "HBP"; OTCQX: "HXBPF") ... 6,625,000 units at $2.05 per unit. , , ... purchase warrant, with each common share purchase warrant entitling the holder to ... price of $2.87 for up to three years after the closing date ...
Cached Biology Technology:Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Akaza Research to Present OpenClinica 3.0 at Upcoming Clinical Research Conferences: SoCRA, SCDM 2Helix BioPharma Closes Private Placement 2Helix BioPharma Closes Private Placement 3
(Date:7/24/2014)... reduce fire hazard in the United States, wildland managers ... shrubs and suppressed trees (ladder fuels). These cuttings ... of low fire danger in order to dispose of ... air pollutants, managers often cover all or part of ... to as agricultural plastic, in order to keep water ...
(Date:7/24/2014)... which life arose have been maintained in our cells today ... Research published today in the Journal of Biological Chemistry ... also in animals still perform ancient reactions thought to have ... billion years ago. , The primordial soup theory suggests that ... of the combination of metals, gases from the atmosphere and ...
(Date:7/24/2014)... Expanding on his work with a new drug that successfully ... of Houston has received a $250,000 grant to expand his ... effort to treat a wider range of autoimmune diseases., Chandra ... biomedical Engineering at UH, previously published a study in Arthritis ... that successfully treated lupus in mice and reduced the number ...
Breaking Biology News(10 mins):Study gives new perspective on agricultural plastic, debris burning, and air quality 2Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3
... and technical publishing business of John Wiley & Sons, Inc. ... Taipei have signed an agreement to closely cooperate and jointly ... The journal will be available online from volume 2011 in ... collections of online resources, used by 10 million people a ...
... Drying of northern wetlands has led to much more severe ... the atmosphere, according to new research led by a University ... Nature Communications , is the first to investigate the effect ... vulnerability of that carbon to burning. "Russia, Indonesia and ...
... by Dr. Jayne S. Weiss, Professor and Chair of Ophthalmology ... found that a defect in a gene involved in a ... of invasive bladder cancer. The findings are published in the ... Cell Biology . It is the featured research of the ...
Cached Biology News:Journal of the Chinese Chemical Society expands international reach with Wiley-VCH 2Drying intensifying wildfires, carbon release ninefold, study finds 2Mutation in gene associated with rare eye disease also contributes to bladder cancer growth 2
G-protein coupled purinergic receptor P2Y8...
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Biology Products: